Advertisement
News
Advertisement

ArQule begins trial of cancer drug candidate

Mon, 12/06/2010 - 8:33am
Mass High Tech: The Journal of New England Technology

ArQule Inc. has enrolled its first patient in a Phase 1 clinical trial aimed at testing ARQ 736, its small molecule inhibitor of the RAF kinases, ArQule officials announced today in a press release.

The trial is expected to evaluate the safety and tolerability of ARQ 736. an inhibitor of the pan-RAF enzyme that has also showed promise as an inhibitor of other mutant kinases. This trial will test ARQ 736 in cancer patients with solid tumors that have the mutant BRAF kinase.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading